|
|
 |
|
Viewing report
|
|
|
|
Sandoz Generics Company Intelligence Report
Espicom Business Intelligence Ltd, March 2009, Pages: 16
Sandoz is currently the second largest generic manufacturer in the world, behind Teva Pharmaceutical Industries. This report provides an insight into the company, reviewing its current business structure and activities.
Sandoz is a subsidiary of Novartis, now headquartered in Germany. The subsidiary was formerly a collection of companies under the Novartis Generics umbrella name, but a major rebranding and reorganisation process began in 2002.
Sandoz is currently the second largest generic manufacturer in the world, behind Teva Pharmaceutical Industries. The company completed its acquisition of Hexal and Eon Labs in June 2005, in one of the generic industry’s largest mergers to date.
Major production sites are in Austria, the USA, Germany and Slovenia. Around two thirds of the company’s workforce is based in Europe. The US subsidiary was formerly known as Geneva Pharmaceuticals, owned by Novartis since 1979. Novartis purchased the major Slovenian producer, Lek, in 2003. Lek has a major presence in the CEE region.
Sandoz is a frontrunner in the development of biosimilar products. Its human growth hormone product, Omnitrope, was approved in 2006, and the company has followed this with European approval of EPO in 2007 and G-CSF in 2008. Lek began constructing a new biotech plant in Slovenia in September 2006, and a new injectables facility has recently been announced in Canada.
Sandoz had sales in 2008 worth US$7.6 billion, 5.4% less than in 2007. The firm reported good growth in markets such as Russia, Brazil and Central and Eastern Europe, but declining sales in the US and some Western European markets. Sales in the US fell by nearly 10%.
This report provides information on the company's active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances and litigation. The company's most recent quarterly and annual financial results are illustrated with comparative figures, charts and a detailed review of the data which allows you to track the company's progress.
Customers who bought this item also bought
Sandoz - PharmaVitae Generics Profile
Sandoz International GmbH - SWOT Analysis
The World Generic Market Report 2008
Cardiovascular Generic Drugs: Prospects and Opportunities to 2012
Teva Pharmaceutical Industries Generics Company Intelligence Report
Injectable Generic Drugs: Prospects & Opportunities to 2013
Sandoz International GmbH: PharmaVitae Model
Emerging Opportunities in Controlled-Release Generic Drugs
Generic Handbook: A Guide to the Generic Drug Industry in the US, 2007 Edition
GenericHandbook - A Guide to the Generic Drug Industry in the US
Injectable Generic Drugs: Prospects and Opportunities to 2010
Emerging Opportunities in Inhalation & Nasal Spray Generic Drugs
|
|
|
|
